Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19467571rdf:typepubmed:Citationlld:pubmed
pubmed-article:19467571lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:19467571lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:19467571lifeskim:mentionsumls-concept:C0334227lld:lifeskim
pubmed-article:19467571lifeskim:mentionsumls-concept:C0014406lld:lifeskim
pubmed-article:19467571lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:19467571lifeskim:mentionsumls-concept:C0045093lld:lifeskim
pubmed-article:19467571lifeskim:mentionsumls-concept:C1511636lld:lifeskim
pubmed-article:19467571lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:19467571lifeskim:mentionsumls-concept:C0301625lld:lifeskim
pubmed-article:19467571pubmed:issue1lld:pubmed
pubmed-article:19467571pubmed:dateCreated2009-9-28lld:pubmed
pubmed-article:19467571pubmed:abstractTextWe examined the efficacy of combination treatments utilizing cytotoxic drugs plus inhibitors to members of the ErbB-ERK signal pathway in human prostate cancer (PCa) LNCaP C-81 cells. Under an androgen-reduced condition, 50nM gemcitabine caused about 40% growth suppression on C-81 cells. Simultaneous treatment of gemcitabine plus 10microM AG825 produced 60% suppression (p<0.03); while, 85% growth inhibition (p<0.02) was seen if AG825 was added to gemcitabine-treated cells after a 24h-interval. Our data thus showed that in androgen-reduced conditions, inhibition of ErbB-2 increases the cytotoxic efficacy of gemcitabine in PCa cells. This finding has significant implications in the choice of drugs for combination therapy as well as the order of administration for treating cancer patients.lld:pubmed
pubmed-article:19467571pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:languageenglld:pubmed
pubmed-article:19467571pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:citationSubsetIMlld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19467571pubmed:statusMEDLINElld:pubmed
pubmed-article:19467571pubmed:monthNovlld:pubmed
pubmed-article:19467571pubmed:issn1872-7980lld:pubmed
pubmed-article:19467571pubmed:authorpubmed-author:ZhangLiLlld:pubmed
pubmed-article:19467571pubmed:authorpubmed-author:BatraSurinder...lld:pubmed
pubmed-article:19467571pubmed:authorpubmed-author:LinFen-FenFFlld:pubmed
pubmed-article:19467571pubmed:authorpubmed-author:LinMing-FongM...lld:pubmed
pubmed-article:19467571pubmed:authorpubmed-author:ZelivianskiSt...lld:pubmed
pubmed-article:19467571pubmed:authorpubmed-author:DavisThomas...lld:pubmed
pubmed-article:19467571pubmed:authorpubmed-author:HaukeRalphRlld:pubmed
pubmed-article:19467571pubmed:authorpubmed-author:DavisJeffrey...lld:pubmed
pubmed-article:19467571pubmed:authorpubmed-author:SchutteRachel...lld:pubmed
pubmed-article:19467571pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19467571pubmed:day18lld:pubmed
pubmed-article:19467571pubmed:volume285lld:pubmed
pubmed-article:19467571pubmed:ownerNLMlld:pubmed
pubmed-article:19467571pubmed:authorsCompleteYlld:pubmed
pubmed-article:19467571pubmed:pagination58-65lld:pubmed
pubmed-article:19467571pubmed:dateRevised2011-9-26lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:meshHeadingpubmed-meshheading:19467571...lld:pubmed
pubmed-article:19467571pubmed:year2009lld:pubmed
pubmed-article:19467571pubmed:articleTitleSuppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment.lld:pubmed
pubmed-article:19467571pubmed:affiliationDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, 68198-5870, USA.lld:pubmed
pubmed-article:19467571pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19467571pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:19467571pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
entrez-gene:2064entrezgene:pubmedpubmed-article:19467571lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19467571lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19467571lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19467571lld:pubmed